What question did this study set out to answer?

This research aims to evaluate the efficacy of NETest2.0® compared to Chromogranin A for monitoring neuroendocrine tumors.

July 11, 2026CancersOpen Access

NETest2.0® Demonstrates Superior Monitoring Performance Compared with Chromogranin A in Neuroendocrine Tumor Surveillance

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates superior disease progression monitoring in neuroendocrine tumors, indicating a potential new standard of care.

This research aims to evaluate the efficacy of NETest2.0® compared to Chromogranin A for monitoring neuroendocrine tumors.
Analyzed paired blood samples from 191 patients with confirmed neuroendocrine tumors enrolled in RegisterNET (NCT02270567).
Compared quantitative RT-PCR derived NETest2.0® scores against serum Chromogranin A levels.
Conducted receiver operating characteristic analysis and logistic regression to assess predictive capabilities.
NETest2.0® showed superior predictive discrimination for disease progression with AUC 0.893, compared to CgA with AUC 0.538 (p < 0.0001).
NETest2.0® thresholds of >0% and >5% achieved AUCs of 0.860 and 0.822, significantly superior to CgA's AUC of 0.553 (p < 0.0001).
Changes in NETest2.0® were the strongest independent predictor of progression (odds ratios: 52.99–61.26, p < 0.0001).

Mashayekhi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial demonstrates superior disease progression monitoring in neuroendocrine tumors, indicating a potential new standard of care.